Insulin, a 51-residue peptide hormone, is an intrinsically amyloidogenic peptide, forming amyloid fibrils in vitro. In the secretory granules, insulin is densely packed together with Zn(II) into crystals of Zn 2 Insulin 6 hexamer, which assures osmotic stability of vesicles and prevents fibrillation of the peptide. However, after release from the pancreatic β-cells, insulin dissociates into active monomers, which tend to fibrillize not only at acidic, but also at physiological, pH values. The effect of co-secreted Zn(II) ions on the fibrillation of monomeric insulin is unknown, however, it might prevent insulin fibrillation. We showed that Zn(II) inhibits fibrillation of monomeric insulin at physiological pH values by forming a soluble Zn(II)-insulin complex. The inhibitory effect of Zn(II) ions is very strong at pH 7.3 (IC 50 = 3.5 μM), whereas at pH 5.5 it progressively weakens, pointing towards participation of the histidine residue(s) in complex formation. The results obtained indicate that Zn(II) ions might suppress fibrillation of insulin at its release sites and in circulation. It is hypothesized that misfolded oligomeric intermediates occurring in the insulin fibrillation pathway, especially in zinc-deficient conditions, might induce autoantibodies against insulin, which leads to β-cell damage and autoimmune Type 1 diabetes.
INTRODUCTION
Insulin, a peptide hormone crucial for glucose metabolism, is produced in the islets of Langerhans by pancreatic β-cells. The peptide is synthesized in the endoplasmic reticulum and concentrated into secretory granules in the Golgi apparatus [1] . After processing by prohormone convertases PC1/3 and PC2 [2] insulin, with zinc, forms water-insoluble crystals of hexamer (Zn 2 Insulin 6 ) in the slightly acidic environment (pH 5.5) of secretory granules [3, 4] . Zn(II) content in the pancreatic β-cells is among the highest in the body, reaching 10 mmol per litre [5] , and one third of it is localized in secretory granules together with insulin [6] . Zn(II) is uploaded to the granules with the assistance of a pancreas-specific zinc transporter ZnT8 localized on the membranes of the granules [7] . ZnT8-knockout mice, where secretory granules of insulin are zinc-depleted, show normal insulin biosynthesis, processing and release, which indicates that Zn(II) ions are not ultimately required in the processes upstream from insulin release [8] .
Amyloidogenic properties of insulin have been known since the 1940s [9, 10] . Fibrillation of insulin has been intensively studied at low pH values and high peptide concentration mostly as a suitable model of protein fibrillation [11] . However, insulin can also fibrillize at physiologically relevant neutral pH values [12, 13] . It is noteworthy that insulin does not form fibrils in the secretory granules, where its concentration is extremely high, reaching 21 mM [14] . Zn(II) ions, the concentration of which is approx. 11 mM in secretory granules [14] , stabilize insulin at high peptide concentrations by forming crystals of Zn 2 Insulin 6 [15, 16] . However, insulin does not fibrillize in the Zn(II)-depleted secretory granules of transgenic ZnT8-knockout mice [8] , indicating that Zn(II) is not the only factor preventing insulin fibrillation in secretory granules. In the absence of Zn(II), insulin still forms oligomeric structures, mainly hexamers, which may prevent insulin fibrillation at high peptide concentrations. Indeed, insulin fibrillation at high peptide concentrations is slower than that at low concentrations, indicating that oligomerization inhibits insulin fibrillation [17] . Insulin is a rare exception within the amyloidogenic peptides, since the propensity for fibrillation of other peptides increases at elevated concentrations. It has also been demonstrated that insulin oligomers must dissociate to monomers before fibrillation [18] . Dissociation of insulin crystals into monomers occurs immediately after secretion of the insulin and also after its injection. Thus a question may arise as to what factors prevent the fibrillation of considerably amyloidogenic insulin monomers in the pancreatic extracellular space, at sites of the injection and also in circulation.
It is noteworthy that, despite widespread use of insulin for treatment of Type 1 diabetes, the incidence of formation of insulin fibrillar deposits at the site of repeated injections is relatively rare. Such a condition, categorized as injection amyloidosis, has been observed at the sites of repeated injection of neutral porcine insulin [19, 20] . As a rule, injection solutions of insulin are supplemented with approx. 0.3 molar equivalent of Zn(II) ions [12, 21] . It has been suggested that co-injected Zn(II) ions might also suppress the fibrillation of monomeric insulin and formation of insulin fibril deposits at the sites of repeated injection as well as in circulation. The influence of Zn(II) on insulin at very low concentrations of the peptide would therefore be of great interest with regard to its action and metabolism.
It is known that metal ions such as Zn(II) and Cu(II) have pronounced effects on the fibrillation of a variety of amyloidogenic peptides such as Alzheimer's amyloid peptide [22] , synuclein [23, 24] , tau protein and prion protein, whereas metal ions can enhance [23, 24] or inhibit fibrillation [25] . In principle, the fibrillation of monomeric insulin can also be suppressed by metal ions, and its suppression by Zn(II) that is co-secreted with insulin can be physiologically relevant. Moreover, fibrillation
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studies of monomeric insulin are also necessary for obtaining a better understanding about the mechanism of insulin fibrillation, as the critical amyloidogenic intermediate in fibrillation of insulin as well as other amyloidogenic peptides/proteins is a partially unfolded monomer [13, 26, 27] . In addition to Zn(II) ions, secretory granules of insulin also contain C-peptide [28] and amylin, which are present in equimolar and approx. 10-fold lower amounts than insulin respectively [29] . Insulin has been shown to interfere with amylin fibrillation [30] , whereas C-peptide affects the pattern of insulin oligomerization [31, 32] and suppresses amylin fibrillation [29] ; however, the effects of the co-released peptides on the fibrillation of insulin have not been determined.
In the present work, we studied systematically the effects of Zn(II) ions, C-peptide, amylin and environmental conditions on the fibrillation of monomeric insulin at physiological pH and demonstrate that Zn(II) ions suppress fibrillation of monomeric insulin through differential stabilization of the monomeric ground state over the partially open transition state leading to amyloidogenesis. It is proposed that Zn(II) ions that are cosecreted together with insulin may prevent fibrillation of insulin at its release sites and in circulation. C-peptide and amylin did not influence the insulin fibrillation.
EXPERIMENTAL

Materials
Lyophilized insulin was purchased from Sigma-Aldrich, amylin was from rPeptide and C-peptide from Nordic BioSite. ThT (thioflavin T) and CuCl 2 · 2H 2 O were from Sigma-Aldrich, and Hepes Ultrapure (molecular biology grade) was from USB Corporation. ZnCl 2 and NaCl (extra pure) were from Scharlau. All solutions were prepared in fresh Milli-Q water.
Sample preparation
A stock solution of insulin was prepared as follows. Insulin was dissolved in 20 mM Hepes, pH 7.3, and 100 mM NaCl at a concentration of 50 μM. After 30 min of incubation at 25
• C, the insulin stock solution was diluted with the same buffer and used for experiments. The oligomeric composition of insulin samples was determined by SEC (size-exclusion chromatography) on a Superdex TM 75 10/300 column (GE Healthcare) connected to anÄkta Purifier system (GE Healthcare) using 20 mM Hepes, pH 7.3, and 100 mM NaCl as the elution buffer.
Monitoring insulin fibrillation by ThT fluorescence
In a standard experiment, a freshly prepared stock solution of insulin was diluted to a final concentration of 2.5 μM in 20 mM Hepes, pH 7.3, and 100 mM NaCl containing 2.5 μM ThT and an appropriate amount of ZnCl 2 . A 450-μl portion of each sample was incubated in a 0.5-cm-path-length quartz cell, equilibrated at 50
• C and agitated with a magnetic stirrer at 250 rev./min. The increase in ThT fluorescence was measured at 480 nm using a λ ex of 440 nm on a PerkinElmer LS-45 fluorescence spectrophotometer equipped with a magnetic stirrer. When insulin was incubated without agitation under similar conditions, the fibrillation process was extremely slow and only a slight increase in ThT fluorescence was observed during prolonged incubation (5 days). Agitation at 250 rev./min was found to be optimal for monitoring the insulin fibrillation, and the effect of agitation was similar to that observed for Alzheimer's amyloid peptide fibrillation [25] . In temperature-dependence studies, temperature was varied from 35
• C to 50
• C. In a second series of experiments, the concentration of insulin was varied from 2.5 to 30 μM.
The kinetic curves of fibrillation were fitted to several sigmoidal functions including Avrami, Gompertz and Boltzmann using the Origin program (OriginLab) and it was found that the Boltzmann equation (eqn 1) provides the best fit of the experimental data and allows calculation of the kinetic parameters of fibrillation:
( 1) where A 1 is the initial fluorescence level, A 2 is the maximum fluorescence and t 0 is the time when fluorescence has reached halfmaximum; 1/τ is the apparent rate constant (k) of the fibril growth and lag time is approximated by t 0 − 2τ as suggested previously [33] . IC 50 values were calculated according to hyperbolic doseresponse curves as described in [25] .
TEM (transmission electron microscopy)
TEM grids were placed on an adhesive solid surface and 3 μl of previously centrifuged (30 min, 12 000 g) peptide solution was pipetted on to each grid and allowed to air dry. Then, drops of 2 % uranylacetate were spotted on to a Parafilm plate and grids were placed on them with the upper side down (to bring the probe and the contrast solution in contact). Probes were kept in uranylacetate for 10 min, then removed and washed with Milli-Q water. After that, excess water was removed with a filter paper and the grids were placed into a special carrier. TEM images from the samples were created on a Selmi EM-125 instrument at 75 kV accelerating voltage and recorded on to high-resolution 60 × 90-mm negative film.
ESI-MS (electrospray ionization MS) measurements
Samples of 1-50 μM insulin in 100 mM ammonium acetate, pH 7.3, incubated for 10 min within a gas-tight syringe at 50 • C, were injected into the electrospray ion source of a QSTAR Elite ESI-Q-TOF (time-of-flight) MS instrument (Applied Biosystems) by a syringe pump at 10 μl/min, and ESI-MS spectra were recorded for up to 5 min in the m/z region 500-3000 Da using the following instrument parameters: ion-spray voltage, 5500 V; source gas, 45 litres/min; curtain gas, 20 litres/min; declustering potential, 60 V; focusing potential, 320 V; and detector voltage, 2300 V. ESI-MS spectra were analysed with the Bioanalyst program (Applied Biosystems).
Equilibrium dialysis
A dialysis experiment was performed with cellulose ester Spectra/Por dialysis-membrane tubing with a molecular-mass cutoff of 1000 Da (Spectrum Laboratories) containing 1.5 ml of 10 μM insulin dissolved in 20 mM Hepes, pH 7.3, and 100 mM NaCl. Dialysis tubing was equilibrated with 500 ml of dialysate solution containing 20 mM Hepes, pH 7.3, 100 mM NaCl and 5 μM ZnCl 2, under agitation for 24 h at 4
• C until equilibrium was achieved. At the end of the experiment, samples were taken from both the inside and outside solutions, acidified with 1 M HCl and analysed for zinc content by atomic absorption spectroscopy on a PerkinElmer 3100 instrument
RESULTS
Monitoring the in vitro formation of insulin fibrils
Insulin fibrillation experiments were performed with freshly solubilized peptide under continuous agitation by monitoring an increase in the fluorescence of the fibril-reactive dye ThT in situ. Under these conditions, a relatively fast increase in ThT fluorescence was observed in accordance with a typical two-phase growth curve (Figure 1 ). The kinetic curves of fibrillation fitted well to the Boltzmann equation (eqn 1), and the midpoint of fibril formation (t 0 ) and the rate constants for the fibrillation process were calculated. Fibrillation was monitored in the presence of 2.5 μM or 10 μM ThT. In a separate experiment, we demonstrated that ThT inhibits insulin fibrillation at concentrations higher than 10 μM. Experiments conducted with 2.5 μM insulin showed that the fibrillation rate constant increased and the duration of the lag phase decreased with increasing temperature (Figure 1 ). The enthalpy of activation E a (− 84 kJ/mol) was found from the slope in the Arrhenius plot (Figure 1, inset) . In further experiments, insulin fibrillation was carried out at 50
• C for practical reasons. Fibrillation curves at 2.5 and 5 μM insulin exposed similar kinetics and lag phases, whereas at concentrations above 10 μM the lag phase increased and the values of the rate constant for fibril growth decreased (Figure 2 ).
Monomer-dimer equilibrium of insulin studied by ESI-MS
The ESI-MS spectrum of 2 μM insulin exposed + 4 and + 5 peaks of monomeric insulin (Figure 3a) , whereas at higher peptide concentrations + 6 and + 7 peaks of dimeric insulin started increasing in the spectra (Figures 3b and 3c) . Monomeric insulin was also the major peak in the spectrum at 50 μM insulin (Figure 3c) , when a substantial proportion of the insulin is supposed to be dimeric. Such a behaviour is indicative of partial dissociation of insulin dimers to monomers during ESI. Moreover, in calculating the K d for insulin dimers it should also be considered that the ionization efficiency of monomers and dimers is not equal in ESI-MS. To obtain the binding isotherm, the fractional content of insulin-dimer peaks was calculated by dividing the summarized area of all insulin-dimer peaks to the summarized areas of all insulin peaks in ESI-MS spectra, and the latter parameter was plotted against insulin concentration (Figure 3d ). The curve obtained was fitted to the equation of the hyperbola and the maximal fractional content F max (0.18 + − 0.03) indicated that 80 % of the insulin dissociated to monomers during ESI, which was expected as the insulin-dimer K d is relatively high. The obtained K d (18.9 + − 0.6 μM) describes the equilibrium of insulindimer dissociation. Our ESI-MS results at pH 7.3 are similar to previous nanospray ESI-MS studies; however, slightly different charge states for different species were observed at pH 3.3 [21] . On the basis of SEC and ESI-MS studies, we can conclude that at 2.5 μM insulin is prevalently monomeric and the effects of insulin oligomerization on the fibrillation kinetics are negligible.
Effects of Zn(II) on the fibrillation of insulin
The effect of Zn(II) on the fibrillation of 2.5 μM insulin was studied at pH 7.3 and 5.5. At pH 7.3, Zn(II) ions decreased the fibrillation rate constant and increased the lag phase of the process in a concentration-dependent manner, whereas the maximal level of ThT fluorescence was not affected (Figure 4a ). The inhibitory effect of Zn(II) characterized by the IC 50 [defined as the Zn(II) concentration at which a halving of the fibrillation rate constant was observed] was equal to 3.5 + − 0.9 μM (Figure 4a) . At pH 5.5, the effect of Zn(II) was much weaker and only an insignificant (10 %) decrease in fibrillation rate was observed in the presence of 20 μM Zn(II) (Figure 4b ).
Effects of C-peptide and amylin on the fibrillation of insulin
Fibrillation of 2.5 μM insulin at pH 7.3 and 50
• C was not affected by 2.5 and 5 μM C-peptide or by 1 μM amylin ( Figure 5 ), indicating that micromolar concentrations of these peptides do not affect fibrillation of monomeric insulin. 
SEC of insulin
SEC analysis showed that injection of 10 μM insulin exposed one peak with an elution volume of 14.5 ml (Figure 6a) , whereas increasing the insulin concentration to 100 μM decreased the elution volume (Figure 6b) , indicative of peptide oligomerization at higher concentrations in agreement with results in the literature [21, 33] . SEC of aliquots of the fibrillation mixture showed that fibrillation is accompanied by the loss of insulin from the solution (Figure 6c ). Fibrillation of 10 μM insulin is completely suppressed in the presence of 5 μM Zn(II) (Figure 4a ) and SEC analysis of the fibrillation mixture in these conditions indicates that the peptide exposes a similar SEC peak as that for the initial solution of 10 μM insulin (Figure 6d) . Moreover, the presence of 5 μM Zn(II) in elution buffer did not cause a shift of the insulin peak in SEC, confirming that 5 μM Zn(II) keeps insulin in a soluble state and does not induce changes in oligomers of insulin under our experimental conditions. 
Equilibrium dialysis
Equilibrium dialysis of 10 μM insulin solution against 5 μM Zn(II) showed that in these conditions insulin binds 0.4 mol of Zn(II) per mol, which corresponds to the value of the K Zn dissociation constant (7.5 μM).
Characterization of insulin fibrils by TEM
Insulin samples showing high ThT fluorescence (agitated for more than 30 min) showed the presence of fibrils in TEM, confirming that the increase of ThT fluorescence reflects peptide fibrillation in our assay. In the samples of 10 μM insulin with added 5 μM Zn(II), almost no aggregates were detected at pH 7.3 after 30 min of agitation; however, at pH 5.5, insulin fibrils were observed (Figure 6e ), which confirms that 5 μM Zn(II) protects insulin from fibrillation at pH 7.3, but not at acidic pH values.
DISCUSSION
The fibrillation of insulin has been studied thoroughly for more than 60 years; however, the majority of studies have been performed with millimolar concentrations of Zn(II)-insulin, which fibrillizes at elevated temperatures and in acidic conditions [12] . Low pH is necessary for fibrillation since, at high millimolar concentrations and neutral pH, Zn(II)-insulin is predominantly in the form of hexamers resistant to fibrillation [18] . The addition of Zn(II) ions that stabilize the hexameric form is commonly used in injection solutions of insulin [12, 21] .
Zinc-free apo-insulin can fibrillize not only at acidic, but also at physiologically relevant, pH values, especially in the presence of chemical compounds such as ethanol, urea and guanidinium that are able to dissociate insulin to monomers [12, 13] . Insulin is a rare exception within the amyloidogenic peptides since its dilution increases the propensity for fibrillation, whereas the fibrillation of other peptides is favoured at high peptide concentrations. Such a behaviour indicates that oligomerization inhibits insulin fibrillation [17] . Thus it follows that the fibrillation of the monomeric biologically active form of insulin, which is the most aggregation-prone form of the peptide, is insufficiently studied.
The behaviour of monomeric insulin can be studied at low peptide concentrations. According to the literature, insulin dimers begin to dissociate when diluted to concentrations below 100 μM [34, 35] and 10 μM insulin is assumed to be essentially monomeric [21] . The K d value for insulin dimers determined by static and dynamic laser light scattering is 12.5 μM at pH 7.3 and 25
• C [36] . Our present ESI-MS studies at 50
• C and pH 7.3 yielded a K d of 18.9 μM, which is in good agreement with the literature. 
Scheme 1 Mechanism for assembly and fibrillogenesis of insulin in the presence of Zn(II) ions
Insulin is hexameric at high peptide concentrations both in the presence and absence of Zn(II). Insulin hexamers dissociate to dimers and monomers at low peptide concentrations, whereas peptide monomers can also bind Zn(II) ions. Monomeric insulin tends to fibrillize via a partially unfolded intermediate that is also assumed to be important for receptor binding. Zn(II)-insulin-monomer formation is off-pathway for fibrillation as it prevents opening of the conformation of monomeric insulin.
Accordingly, at 2.5 μM, insulin is prevalently monomeric and the equilibrium concentration of dimers is approx. 0.22 μM.
Our results demonstrated that fibrillation of insulin depends only slightly on the insulin concentration in the range 2.5-10 μM, whereas at higher concentrations the fibrillation lag time increases and the fibrillation rate decreases. The inhibition of fibril formation at higher insulin concentrations indicates that the formation of insulin oligomers is an off-pathway process for fibrillation. Secondly, as the rate constant for fibril growth at concentrations below 10 μM is constant, we can conclude that the rate-limiting step of fibril growth is most probably connected with some intramolecular event such as conformational change. Indeed, the fibrillation of monomeric insulin is characterized by a relatively large E a value of − 84 kJ/mol, indicating that the formation of a fibrillation-competent structure is accompanied by substantial conformational changes. The native conformation of insulin in Zn(II) 2 Insulin 6 hexamers [37] as well as its monomers is essentially α-helical [38] . Multiple techniques including FTIR (Fourier-transform infrared) and CD demonstrate that insulin fibril formation is accompanied by extensive unfolding of the molecule to allow conversion from an α-helical into a β-sheet conformation [11, 21] , necessary to build up the cross-β framework of insulin fibrils [39] . Apparently, such a conformational change in disulfide-linked native insulin is causing the observed large E a .
From the compounds co-released with insulin, only Zn(II) exposed a pronounced inhibitory effect upon the fibrillation of monomeric insulin at pH 7.3. An IC 50 of 3.5 μM indicates that Zn(II) ions already inhibit fibrillation at a low micromolar concentration and the addition of a 4-fold excess of Zn(II) almost completely suppressed the formation of insulin fibrils. Equilibrium dialysis of insulin against 5 μM Zn(II) confirmed that the inhibitory effect is in the same range as the Zn(II) binding affinity of insulin, K Zn (7.5 μM) at low concentrations. At pH 5.5, the inhibitory effect of Zn(II) was much weaker as 20 μM Zn(II) did not affect the fibrillation rate constant and caused only a slight increase of the lag phase. The pHdependence points towards participation of histidine residue(s) in the Zn(II)-induced inhibition of insulin fibrillation. It is known that the histidine residue at position B10 that is located in the vicinity of the six-residue B-chain segment (B12-B17) contributing to the formation of cross-β structure [40] participates in the binding of Zn(II) ions. It could be suggested that binding of Zn(II) to His 10 may hinder the formation of a β-sheetrich conformation compatible for fibrillation nearby. Thus the interaction of Zn(II) with the monomeric insulin inhibits its fibrillation most probably through differential stabilization of the monomeric ground state over the partially open conformation that is necessary for fibrillation. A schematic model describing the effect of Zn(II) ions on the fibrillation of insulin is presented in Scheme 1.
Biological context
Insulin is present in the secretory granules at a extremely high concentration reaching 21 mM [14] . The main factor preventing insulin fibrillation in secretory granules is the formation of stable Zn(II) 2 Insulin 6 hexamers (in zinc-enriched granules) or insulin oligomers (in zinc-depleted granules). Nevertheless, the fibrillation may also occur at the sites of its release, where insulin dissociates to monomers, which are the most fibrillationprone form of the peptide. Based on the present results, we suggest that Zn(II) ions that are co-secreted with insulin from pancreatic β-cells might help insulin to avoid fibrillation at its release sites after dissociation of hexamers. Insulin fibrillation is a physiologically undesirable process for many reasons. First, fibrillation removes monomeric insulin out of secretion and prevents its interaction with insulin receptors. Secondly, insulin fibrillation occurs via intermediate misfolded oligomers [41, 42] and prefibrillar aggregates, composed of 500 or more monomers and the dimensions of which might reach 14 Å (1 Å=0.1 nm) [43] . These intermediates might be cytotoxic, as demonstrated in the case of Alzheimer's amyloid peptides [44] and also in the case of many other peptides and proteins. Besides being cytotoxic, these large misfolded oligomeric intermediates can also be immunogenic if they occur in the circulation. Such a scenario is feasible in the case of insulin.
Type 1 diabetes is an autoimmune disease that is characterized by the presence of autoantibodies against insulin and some other pancreatic proteins. These diabetes-related autoantibodies are present already in the preclinical asymptomatic latent period of the disease, and several studies have shown that insulin autoantibodies are the first to appear in young children, implying that insulin may be the primary autoantigen in most cases of childhood Type 1 diabetes [45] . The reason why autoantibodies that attack and destroy pancreatic β-cells are generated is currently largely unknown. It cannot be ruled out that the pathology is related to the generation of antibodies against misfolded insulin oligomers occurring as on-pathway intermediates during insulin fibrillation. Based on the present results, it can be hypothesized that Zn(II) ions co-secreted from pancreatic β-cells protect the organism from insulin fibrillation and formation of intermediary non-native insulin oligomers/aggregates. It can also be hypothesized that disturbances in zinc metabolism and especially zinc deficiency might enhance insulin fibrillation with intermediary formation of misfolded oligomers, which are immunogenic and might induce the generation of insulin autoantibodies. Currently, there is no direct evidence confirming the suggested hypothesis; however, epidemiological studies associate diabetes with zinc deficiencies, which is in good agreement with the suggested hypothesis.
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